One-and two-stage designs for phase II window studies

Statistics in Medicine

Volumn 26, Issue 13, 2007, Pages 2604-2614

  Chang, Myron N ^a   Devidas, Meenakshi ^a   Anderson, James ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Average sample number; Likelihood ratio test; Multinomial distribution; Power function

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GROWTH; CANCER RESEARCH; CANCER RESISTANCE; CANCER STATISTICS; CHILD; CHILDHOOD DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EXPERIMENTAL DESIGN; HUMAN; LYMPHATIC LEUKEMIA; PHASE 2 CLINICAL TRIAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, STATISTICAL; UNITED STATES;

EID: 34249708815     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2741     Document Type: Article

References (14)

1. Horowitz ME, Etcubanas E, Christensen ML, Houghton JA, George SL, Green AA, Houghton PJ. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. Journal of Clinical Oncology 1988; 6(2):308-314.
2. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a children's oncology group study. Journal of Clinical Oncology 2004; 22(8):1398-1403.
3. Ferguson WS, Harris MB, Goorin AM, Gebhardt MC, Link MP, Shochat SJ, Siegal GP, Devidas M, Grier HE. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: pediatric oncology group trial. Journal of Pediatric Hematology Oncology 2001; 23(6):340-348.
4. Mantadakis E, Herrera L, Leavey PJ, Bash RO, Winick NJ, Kamen BA. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. Journal of Clinical Oncology 2000; 18(13):2576-2581.
5. Chantada GL, Fandino A, Mato G, Casak S. Phase II window of idarubicin in children with extraocular retinoblastoma. Journal of Clinical Oncology 1999; 17(6):1847-1850.
6. Kadota RP, Stewart CF, Horn M, Kuttesch Jr JF, Burger PC, Kepner JL, Kun LE, Friedman HS, Heideman RL. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. Journal of Neuro-oncology 1999; 43(1):43-47.
7. Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a pediatric oncology group study. Journal of Clinical Oncology 1994; 12(8):1616-1620.
8. Razzouk BI, Heideman RL, Friedman HS, Jenkins JJ, Kun LE, Fairclough DL, Horowitz ME. A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer 1995; 75(11):2762-2767.
9. Smith MA, Anderson B. Phase II window studies: 10 years of experience and counting. Journal of Pediatric Hematology Oncology 2001; 23(6):334-337.
10. Zee B, Melnychuk D, Dancey J, Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. Journal of Biopharmaceutical Statistics 1999; 9(2):351-363.
11. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995; 51(4):1372-1383.
12. Conaway M, Petroni G. Bivariate sequential designs for phase II trials. Biometrics 1995; 51(2):656-664.
13. Conaway M, Petroni G. Designs for phase II trials allowing for a trade-off between response and toxicity. Biometrics 1996; 52(4):1375-1386.
14. Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E. Multinomial phase II trial designs. Journal of Clinical Oncology 2002; 20(2):599.